STAT+: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more
An FDA advisory panel concluded clinical data for a Capricor treatment for Duchenne muscular dystrophy did not provide “substantial evidence” of efficacy
<p>An FDA advisory panel concluded clinical data for a Capricor treatment for Duchenne muscular dystrophy did not provide “substantial evidence” of efficacy</p>